Search
Paclitaxel Treatment Options
A collection of 2028 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
1657 - 1668 of 2028
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known whether giving paclitaxel for a shorter period of time is as effective as a standard course of treatment for advanced ovarian cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel given for 3 months with that of paclitaxel given for 12 months in treating patients who have stage III or stage IV ovarian, fallopian tube, or pr... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/07/2014
Locations: MBCCOP - Gulf Coast, Mobile, Alabama +92 locations
AMG 386 Drug-Drug Interaction Study With Paclitaxel
Completed
The purpose of this study is to evaluate the pharmacokinetics of paclitaxel when given alone and in combination with AMG 386 to determine whether AMG 386 alters the pharmacokinetics of paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2014
Locations: University of Colorado Cancer Center, Aurora, Colorado +1 locations
Conditions: Advanced Solid Tumors
Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer
Completed
This randomized phase II trial is studying how well giving carboplatin and paclitaxel together with cetuximab and/or cixutumumab (IMC-A12) works in treating patients with stage IIIB or stage IV non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab and cixutumumab, can block tumor growth in different... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2014
Locations: Stanford University Hospitals and Clinics, Stanford, California +248 locations
Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors
Completed
This study will evaluate PTK787, a new oral drug that stops blood vessel development, in combination with Paclitaxel in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/10/2014
Locations: Indiana University Simon Cancer Center, Indianapolis, Indiana
Conditions: Neoplasm Metastasis, Carcinoma
Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye
Completed
This phase II trial is studying how well sorafenib works when given together with carboplatin and paclitaxel in treating patients with stage IV melanoma of the eye. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib may help carboplatin and paclitaxel work better by making tumor cells more sensitive to the drugs. Sorafenib may also stop the growth of mel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2014
Locations: Southwest Oncology Group, San Antonio, Texas
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma
A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)
Terminated
The purpose of this study is to evaluate if a maximum dose of 100 mg of dasatinib with concurrent chemoradiation can be tolerated in patients with chemotherapy naive stage III NSCLC in separate cohorts of locally advanced and potentially resectable disease.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
07/24/2014
Locations: Lifespan Hospitals, Providence, Rhode Island
Conditions: Non-Small Cell Lung Cancer
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Completed
The FB-8 study is designed as an open label, single arm, Phase I dose-escalation study evaluating the combination of weekly paclitaxel with neratinib and trastuzumab in women with metastatic, HER2-positive breast cancer. The primary aim of this study is to determine the safety and tolerability of the three-drug combination.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/07/2014
Locations: Cancer Institute of New Jersey, New Brunswick, New Jersey +3 locations
Conditions: Breast Cancer
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may help paclitaxel work better by making tumor cells more sensitive to the drug. Lapatinib may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving lapatinib together with paclitaxel may kill more tumor cells.
PURPOSE: This phase I trial is studying the side eff... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2014
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Conditions: Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer, Extragonadal Germ Cell Tumor, Gastric Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
Completed
Primary Objectives: o Run-in Phase: Determine a dose of EP-100 at which the initial benefit/risk of paclitaxel combined with EP-100 can be studied. o Randomized Phase: Compare the anti-tumor effects of EP-100 combined with weekly paclitaxel versus paclitaxel alone in patients with ovarian cancer. Secondary Objectives: o Randomized Phase: Quantify any significant changes in the safety profile of weekly paclitaxel alone compared to the doublet combination of paclitaxel with EP-100. o Determine an... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/09/2014
Locations: Investigational Site Number 840001, Greenbrae, California +14 locations
Conditions: Ovarian Cancer Recurrent
Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
Terminated
Objectives:
Primary:
To estimate the efficacy of bevacizumab and paclitaxel in patients with recurrent small cell, large cell, and neuroendocrine cervical and uterine cancers, as measured by progression-free survival.
Secondary:
1. To estimate the efficacy of bevacizumab and paclitaxel in patients with recurrent small cell, large cell, and neuroendocrine cervical and uterine cancers, as measured by overall survival.
2. To determine the response rates in patients with recurrent small cell, la... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
06/05/2014
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Cervical Cancer, Uterine Cancer
Papillary Serous Carcinoma of the Endometrium
Completed
Primary Objectives:
* To evaluate the results of Paclitaxel and pelvic radiation in pelvic confined papillary serous carcinoma of the endometrium for both local control and overall survival.
* To evaluate the toxicity of Paclitaxel and pelvic radiation.
* To collect and evaluate patients' quality of life/symptom assessment data.
Gender:
FEMALE
Ages:
All
Trial Updated:
05/30/2014
Locations: M. D. Anderson Cancer Center - Orlando, Orlando, Florida +1 locations
Conditions: Endometrial Cancer
Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
Terminated
This randomized phase III trial is studying carboplatin, paclitaxel, radiation therapy, and thalidomide to see how well they work compared to carboplatin, paclitaxel, and radiation therapy alone in treating patients with newly diagnosed stage III non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor. It is not yet kno... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2014
Locations: Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Ft. Smith, Arkansas +235 locations
Conditions: Lung Cancer
1657 - 1668 of 2028